Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
27460088
DOI
10.1007/s13277-016-5177-9
PII: 10.1007/s13277-016-5177-9
Knihovny.cz E-resources
- Keywords
- Long non-coding RNA, Migration, Muscle-invasive bladder cancer, Prognosis, Proliferation, TUG1,
- MeSH
- Apoptosis MeSH
- Cell Cycle MeSH
- Neoplasm Invasiveness MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Humans MeSH
- RNA, Small Interfering genetics MeSH
- RNA, Messenger genetics MeSH
- Biomarkers, Tumor genetics MeSH
- Tumor Cells, Cultured MeSH
- Urinary Bladder Neoplasms genetics pathology MeSH
- Muscle Neoplasms genetics pathology MeSH
- Cell Movement * MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Cell Proliferation * MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- RNA, Long Noncoding antagonists & inhibitors genetics MeSH
- Neoplasm Staging MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- RNA, Small Interfering MeSH
- RNA, Messenger MeSH
- Biomarkers, Tumor MeSH
- RNA, Long Noncoding MeSH
- TUG1 long noncoding RNA, human MeSH Browser
Long non-coding RNA TUG1 is involved in the development and progression of a variety of tumors. Little is known about TUG1 function in high-grade muscle-invasive bladder cancer (MIBC). The aims of our study were to determine expression levels of long non-coding RNA TUG1 in tumor tissue, to evaluate its relationship with clinico-pathological features of high-grade MIBC, and to describe its function in MIBC cells in vitro. TUG1 expression levels were determined in paired tumor and adjacent non-tumor bladder tissues of 47 patients with high-grade MIBC using real-time PCR. Cell line T-24 and siRNA silencing were used to study the TUG1 function in vitro. We observed significantly increased levels of TUG1 in tumor tissue in comparison to adjacent non-tumor bladder tissue (P < 0.0001). TUG1 levels were significantly increased in metastatic tumors (P = 0.0147) and were associated with shorter overall survival of MIBC patients (P = 0.0241). TUG1 silencing in vitro led to 34 % decrease in cancer cell proliferation (P = 0.0004) and 23 % reduction in migration capacity of cancer cells (P < 0.0001). We did not observe any significant effects of TUG1 silencing on cell cycle distribution and number of apoptotic cells. Our study confirmed overexpression of TUG1 in MIBC tumor tissue and described its association with worse overall survival in high-grade MIBC patients. Together with in vitro observations, these data suggest an oncogenic role of TUG1 and its potential usage as biomarker or therapeutic target in MIBC.
See more in PubMed
Eur Urol. 2014 Jul;66(1):59-73 PubMed
Urol Oncol. 2014 Jul;32(5):637-44 PubMed
FEBS Lett. 2015 Oct 7;589(20 Pt B):3175-81 PubMed
Oncogene. 2009 Jan 15;28(2):195-208 PubMed
RNA Biol. 2012 Jun;9(6):703-19 PubMed
Tumour Biol. 2015 Mar;36(3):1643-51 PubMed
Curr Biol. 2005 Mar 29;15(6):501-12 PubMed
J Surg Oncol. 2013 Apr;107(5):555-9 PubMed
J Transl Med. 2012 May 21;10:103 PubMed
Oncotarget. 2014 Sep 30;5(18):8027-38 PubMed
Asian Pac J Cancer Prev. 2013;14(4):2311-5 PubMed
Cell Death Dis. 2016 Feb 25;7:e2109 PubMed
J Transl Med. 2016 Feb 08;14 :42 PubMed
CA Cancer J Clin. 2015 Mar;65(2):87-108 PubMed
Mol Cancer. 2015 Sep 04;14:165 PubMed
Nat Rev Urol. 2015 Oct;12(10):536 PubMed
Tumour Biol. 2015 Jun;36(6):4851-9 PubMed
Cancer Res. 2013 Feb 1;73(3):1180-9 PubMed
Cell Death Dis. 2014 May 22;5:e1243 PubMed
Urol Oncol. 2015 Apr;33(4):187-95 PubMed
Nature. 2010 Apr 15;464(7291):1071-6 PubMed
